Back to top
more

Bruker (BRKR)

(Delayed Data from NSDQ)

$30.43 USD

30.43
3,943,937

-0.73 (-2.34%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $30.48 +0.05 (0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 1% (244 out of 244)

Industry: Instruments - Scientific

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

David Bartosiak headshot

Five Runaway Breakout Stocks to Buy

by David Bartosiak

With the market at all-time highs again, the rich get richer as stocks continue to breakout.

Zacks Equity Research

Here's Why Bruker (BRKR) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Bruker (BRKR) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Universal Display, Bruker, Match, j2 and Ciena

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Universal Display, Bruker, Match, j2 and Ciena

Swarup Gupta headshot

5 Top Tech Gainers of 1H19

by Swarup Gupta

The Technology Select Sector SPDR Fund (XLK) is the leading performer among the S&P 500's 11 sectors year to date.

Zacks Equity Research

Here's Why You Should Add Bruker (BRKR) to Your Portfolio

by Zacks Equity Research

Investor confidence in Bruker stock (BRKR) is high on substantial potential of MALDI Biotyper.

Zacks Equity Research

Teleflex (TFX) Shares Down on Respiratory Care Product Recall

by Zacks Equity Research

Teleflex (TFX) issued a statement saying consumers who own the tampered product should immediately discontinue use and return all affected products.

Zacks Equity Research

Bruker (BRKR) Hits a 52-Week High on Solid Growth Drivers

by Zacks Equity Research

Bruker (BRKR) gains from several crucial product launches and acquisitions.

Zacks Equity Research

All You Need to Know About Bruker (BRKR) Rating Upgrade to Strong Buy

by Zacks Equity Research

Bruker (BRKR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Methode Electronics (MEI) Q4 Earnings Lag, Sales Up Y/Y

by Zacks Equity Research

Methode Electronics' (MEI) fourth-quarter fiscal 2019 results suffer from weak automotive sales stemming from lower demand for passenger cars.

Zacks Equity Research

Bruker (BRKR) Launches the MALDI Biotyper Sirius System

by Zacks Equity Research

The launch is a milestone for Bruker (BRKR) in assay research and clinical studies for fast antibiotic-resistance testing.

Zacks Equity Research

IDEXX (IDXX) Gains Traction From Solid CAG, Global Strength

by Zacks Equity Research

IDEXX (IDXX) consistently benefits from strong organic growth, driven by robust sales at the CAG business, fueled by a firm global Catalyst adoption.

Zacks Equity Research

Here's Why You Should Add Hologic (HOLX) to Your Portfolio

by Zacks Equity Research

Hologic (HOLX) is generating consistent positive results, courtesy of growth initiatives.

Zacks Equity Research

Hologic (HOLX) Inks Deal to Acquire SuperSonic Imagine

by Zacks Equity Research

The acquisition of SuperSonic Imagine is in sync with Hologic's (HOLX) strategy to provide wide-ranging screening, interventional and surgical solutions.

Zacks Equity Research

QIAGEN Inks Distribution Deal With Mckesson Medical-Surgical

by Zacks Equity Research

The distribution agreement will enable QIAGEN (QGEN) to expand reach in the healthcare market.

Zacks Equity Research

Haemonetics on a High Owing to Firm Plasma Arm, Global Growth

by Zacks Equity Research

Continued traction in new business wins and expansion of geographies are lifting Haemonetics' (HAE) performance of late.

Zacks Equity Research

Here's Why You Should Invest in Haemonetics (HAE) Stock Now

by Zacks Equity Research

Haemonetics (HAE) benefits from impressive uptick of Hemostasis Management revenues.

Zacks Equity Research

NuVasive Grows on Strong Product Adoption Amid Pricing Woe

by Zacks Equity Research

Introduction of multiple products within the Spinal Hardware, balanced revenue growth across key operating segments and robust international sales perk up NuVasive's (NUVA) share price.

Zacks Equity Research

Haemonetics' Plant Sell-Off to CLS Plasma to be Strategic Fit

by Zacks Equity Research

This impending divestment remains integral to Haemonetics' (HAE) asset optimization strategy that aims at improving its operational performance and focusing on core competencies.

Zacks Equity Research

Teleflex (TFX) Hits New 52-Week High on Solid Growth Drivers

by Zacks Equity Research

Teleflex (TFX) gains from acquisition of NeoTract and Vascular Solutions.

Zacks Equity Research

NuVasive Launches Titanium Spine Implant Modulus TLIF-O

by Zacks Equity Research

The launch of Modulus TLIF-O is expected to boost the AMS portfolio of NuVasive (NUVA).

Zacks Equity Research

Align (ALGN), Sraumann Cease Talks on iTero Distribution (Revised)

by Zacks Equity Research

The termination of discussion related to Straumann's iTero distribution is a setback for Align Technologies (ALGN), which is currently focusing on expanding its market base for scanners.

Zacks Equity Research

LabCorp Diagnostics Shows Robust Growth Amid Price Declines

by Zacks Equity Research

LabCorp's (LH) Diagnostics business sees an organic uptick in terms of both revenues and volumes in spite of further price reductions.

Zacks Equity Research

Align (ALGN) Ceases Straumann Distribution Deal, Shares Slip

by Zacks Equity Research

The termination of the Straumann agreement comes as a setback for Align Technologies (ALGN), which is currently focusing on expanding its market base for scanners.

Zacks Equity Research

Abbott (ABT) Hits New 52-Week High on Solid Growth Drivers

by Zacks Equity Research

Abbott (ABT) gains from expansion of product portfolio and several regulatory clearances.

Zacks Equity Research

Here's Why You Should Invest in Teleflex (TFX) Stock Now

by Zacks Equity Research

Teleflex (TFX) benefits from rising investors' confidence, courtesy of the NeoTract acquisition.